Genfit (GNFTF) News Today $3.54 0.00 (0.00%) As of 01/29/2025 Add Compare Share Share Headlines Stock AnalysisChartShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Genfit Advances Liver Disease Programs Amid Promising DevelopmentsNovember 14, 2024 | markets.businessinsider.comGenfit (NASDAQ:GNFT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comGNFTF Genfit S.A.September 13, 2024 | seekingalpha.comGilead exits J&J royalty deal for liver drug ahead of potential FDA nodAugust 10, 2024 | msn.comIpsen liver disease drugs endorsed in EUJuly 26, 2024 | msn.comGenfit (OTC: GNFTF)April 16, 2024 | fool.comInventiva resumes Phase 3 study for NASH drug, stock up 6%March 8, 2024 | msn.comOptimistic Outlook for Genfit: Justine Telliez Raises Target Price Amid Positive Drug DevelopmentsDecember 11, 2023 | markets.businessinsider.comBuy Rating Affirmed for Genfit SA on Strong Elafibranor Efficacy and Favorable Regulatory ProspectsDecember 9, 2023 | markets.businessinsider.comGENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)December 8, 2023 | markets.businessinsider.comGenfit Share Price (GNFT.PA)November 15, 2023 | lse.co.ukIpsen, Genfit Drug Fights Liver Disease Progression, Phase-Three Trial FindsNovember 14, 2023 | marketwatch.comGenfit reports 9M resultsNovember 12, 2023 | seekingalpha.comKepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)September 23, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on Genfit SA (GNFT)July 4, 2023 | markets.businessinsider.comGenfit Shares Jump 27% After Positive Phase 3 Trial ResultsJune 30, 2023 | marketwatch.comU.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver diseaseJune 30, 2023 | msn.comGenfit Gears Up For Primary Biliary Cholangitis Trial DataJune 7, 2023 | markets.businessinsider.comGenfit (GNFTF) Receives a Buy from Kepler CapitalJune 3, 2023 | markets.businessinsider.comODDO BHF Maintains Genfit (EPA:GNFT) Buy RecommendationApril 21, 2023 | msn.comSVB SECURITIES Maintains Genfit (EPA:GNFT) Outperform RecommendationApril 21, 2023 | msn.comGENFIT Announces 2023 Financial CalendarJanuary 24, 2023 | benzinga.comA Long Wait For Genfit May Be Worth ItNovember 23, 2022 | seekingalpha.comGENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of VersantisSeptember 29, 2022 | nz.finance.yahoo.comGENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver DiseasesSeptember 19, 2022 | finance.yahoo.comGenfit Tortures Fatty Liver Drug to Extract Positive Results From Failed StudySeptember 14, 2022 | thestreet.comFDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 13, 2022 | finance.yahoo.comGenfit's French Fans Fume Following Failure of Fatty Liver DrugSeptember 12, 2022 | thestreet.comGenfit S.A. (GNFT)September 9, 2022 | finance.yahoo.comGNFT.OQ - Genfit SA (ADR) | Stock Price & Latest News | ReutersAugust 20, 2022 | reuters.comAnalyzing Genfit's Short InterestAugust 19, 2022 | msn.comNew Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The ...November 3, 2021 | apnews.comNew Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®November 2, 2021 | finance.yahoo.com Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFTF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFTF Media Mentions By Week GNFTF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNFTF News Sentiment▼1.000.72▲Average Medical News Sentiment GNFTF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNFTF Articles This Week▼10▲GNFTF Articles Average Week Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFTF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Apollomics News Today Arno Therapeutics News Today Ascentage Pharma Group International News Today Ascletis Pharma News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNFTF) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMan Who Called Nvidia Says: “Your Retirement Is Inside This Building.”In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.